NASDAQ : VIR
Vir Biotechnology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 11.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.99B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.89B |
| Enterprise Value | 1.45B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 169.22M |
| Shares Outstanding | 169.22M |
| Shares Change (YoY) | +8.01% |
| Shares Change (QoQ) | +14.61% |
| Owned by Insiders (%) | 4.23% |
| Owned by Institutions (%) | 70.46% |
| Float | 129.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.26 |
| Forward PS | 46.17 |
| PB Ratio | 1.95 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.04 |
| Quick Ratio | 5.67 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.08% |
| Return on Assets (ROA) | -14.51% |
| Return on Invested Capital (ROIC) | -57.32% |
| Return on Capital Employed (ROCE) | -24.96% |
| Weighted Average Cost of Capital (WACC) | 12.40% |
| Revenue Per Employee | $826,232 |
| Profits Per Employee | -$685,774 |
| Employee Count | 367 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 380,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +86.75% |
| 50-Day Moving Average | 10.97 |
| 200-Day Moving Average | 9.55 |
| Relative Strength Index (RSI) | 51.73 |
| Average Volume (20 Days) | 1,737,068 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16.24M |
| Short Previous Month | 14.98M |
| Short % of Shares Out | 9.60% |
| Short % of Float | 12.51% |
| Short Ratio (days to cover) | 7.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 303.23M |
| Gross Profit | -180.09M |
| Operating Income | -279.47M |
| Pretax Income | -251.30M |
| Net Income | -251.68M |
| EBITDA | -267.96M |
| EBIT | -279.47M |
| Loss Per Share | -$1.70 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 532.73M |
| Total Debt | 93.27M |
| Net Cash | 439.45M |
| Net Cash Per Share | $2.60 |
| Equity (Book Value) | 982.49M |
| Book Value Per Share | 5.81 |
| Working Capital | 478.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -202.51M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 11.51M |
| Net Borrowing | n/a |
| Free Cash Flow | -203.59M |
| FCF Per Share | -$1.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | -59.39% |
| Operating Margin | -92.16% |
| Pretax Margin | -82.87% |
| Profit Margin | -83.00% |
| EBITDA Margin | -88.37% |
| EBIT Margin | -92.16% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.01% |
| Shareholder Yield | -8.01% |
| Earnings Yield | -15.19% |
| FCF Yield | -10.73% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.00 |
| Price Target Difference | 87.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 13.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.29 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |